 | |
 | |
| Combination of | |
|---|---|
| Ketamine | NMDA receptor antagonist |
| Temsirolimus | mTOR inhibitor |
| Clinical data | |
| Other names | FREE-001; FREE001; Temsirolimus/ketamine |
Ketamine/temsirolimus (developmental code name FREE001 or FREE-001) is a combination of ketamine, an NMDA receptor antagonist, and temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, which is under development for the treatment of major depressive disorder. [1] [2] [3] [4] It is being developed to prolong the antidepressant effects of ketamine and esketamine, by 2 to 3 times, from 2 to 7 days to 14 days in terms of preliminary clinical findings. [3] The combination is being developed by Freedom Biosciences. [1] [2] [3] [4] As of April 2024, it is in phase 2 clinical trials. [1] [2] [3] [4]
